Related Experiment Video

Updated: May 2, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

6.5K

Better therapeutic trials in ovarian cancer

Michael A Bookman1, C Blake Gilks, Elise C Kohn

  • 1Affiliations of authors: University of Arizona Cancer Center, Tucson, AZ (MAB); Department of Pathology and Laboratory Medicine, Vancouver General Hospital, Vancouver, BC, Canada (CBG); Molecular Signalling Section, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD (ECK); Director, Policy and Advocacy, Prevent Cancer Foundation, Alexandria, VA (KOK); Pathology and Laboratory Medicine (DH) and Department of Medical Oncology (KDS), University of British Columbia, Vancouver, BC, Canada (DH); Department of Medical Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY (CA); Department of Medicine, Harvard Medical School, Massachusetts General Hospital, Boston, MA (MJB); CR UK/UCL Cancer Trials Centre, University College London Cancer Institute, London, UK (JAL); Division of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, ON, Canada (AMO).

Journal of the National Cancer Institute
|March 15, 2014
PubMed

Insights

The Ovarian Task Force recommended integrated clinical trials for ovarian cancer, focusing on targeted therapies and efficient drug screening. This approach aims to accelerate the development of new treatments for gynecologic cancers.

Area of Science:

  • Gynecologic Oncology
  • Clinical Trial Design
  • Translational Research

Background:

  • The Ovarian Task Force of the Gynecologic Cancer Steering Committee convened to address challenges in ovarian cancer research.
  • Key stakeholders, including researchers, industry, regulators, and patient advocates, participated.
  • The evolving landscape of scientific, regulatory, and funding priorities necessitated a strategic planning meeting.

Purpose of the Study:

  • Identify key tumor types, molecular pathways, and biomarkers for targeted drug development in ovarian cancer.
  • Review and improve strategies for early-phase screening and therapeutic evaluation of novel agents.
  • Optimize the design of randomized clinical trials for gynecologic cancers.

Main Methods:

  • Convened a clinical trials planning meeting with diverse international experts.
  • Facilitated panel discussions on disease types, early-phase trials, and randomized trial design.
  • Formulated key recommendations based on summarized discussions.

Main Results:

  • Endorsed a more integrated and efficient approach for screening new agents.
  • Advocated for smaller, selective randomized trials in specific disease settings.
  • Supported collaborative funding models and enhanced public awareness for study enrollment.

Conclusions:

  • A streamlined approach to clinical trials is crucial for advancing ovarian cancer therapies.
  • Collaboration between industry and national networks, alongside patient advocacy, can accelerate drug development.
  • Future research should focus on targeted interventions and optimized trial designs for improved patient outcomes.

More Related Videos

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

13.8K
In vivo Imaging and Therapeutic Treatments in an Orthotopic Mouse Model of Ovarian Cancer07:46

In vivo Imaging and Therapeutic Treatments in an Orthotopic Mouse Model of Ovarian Cancer

Published on: August 17, 2010

34.7K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
8.5K
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.7K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.5K